Prostate Cancer

Phase III trial of GVAX prostate cancer vaccine initiated

Published in Cancer Weekly, August 10th, 2004

Cell Genesys, Inc., (CEGE) announced that enrollment has been initiated for a multicenter phase III clinical trial of GVAX prostate cancer vaccine in patients with metastatic hormone-refractory prostate cancer.

This trial, referred to as VITAL-1, is based on the promising findings from two previously conducted phase II trials of the vaccine in over 100 patients with advanced prostate cancer. The trial will compare GVAX prostate cancer vaccine to docetaxel (Taxotere) chemotherapy and is expected to enroll approximately 600 patients at more than 50 medical centers across the United States.

In May 2004, Cell Genesys received a Special Protocol...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-08-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry